TRIPTODUR CARE Trademark

Trademark Overview

On Friday, May 2, 2025, a trademark application was filed for TRIPTODUR CARE with the United States Patent and Trademark Office. The USPTO has given the TRIPTODUR CARE trademark a serial number of 99167826. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Friday, May 2, 2025. This trademark is owned by Debiopharm International SA. The TRIPTODUR CARE trademark is filed in the Advertising, Business and Retail Services, Insurance & Financial Services, and Medical & Beauty Services & Agricultural Services categories with the following description:

providing medical information relating to hormonal disorders and pharmaceuticals used to treat endocrine disorders indicated for the treatment of precocious puberty, including patient support services and affordability programs, drug access, and administration guidance

providing medical information relating to hormonal disorders and pharmaceuticals used to treat endocrine disorders indicated for the treatment of precocious puberty, including patient support services and affordability programs, drug access, and administration guidance

providing medical information relating to hormonal disorders and pharmaceuticals used to treat endocrine disorders indicated for the treatment of precocious puberty, including patient support services and affordability programs, drug access, and administration guidance
triptodur care

General Information

Serial Number99167826
Word MarkTRIPTODUR CARE
Filing DateFriday, May 2, 2025
Status630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
Status DateFriday, May 2, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and Servicesproviding medical information relating to hormonal disorders and pharmaceuticals used to treat endocrine disorders indicated for the treatment of precocious puberty, including patient support services and affordability programs, drug access, and administration guidance
Goods and Servicesproviding medical information relating to hormonal disorders and pharmaceuticals used to treat endocrine disorders indicated for the treatment of precocious puberty, including patient support services and affordability programs, drug access, and administration guidance
Goods and Servicesproviding medical information relating to hormonal disorders and pharmaceuticals used to treat endocrine disorders indicated for the treatment of precocious puberty, including patient support services and affordability programs, drug access, and administration guidance

Classification Information

International Class035 - Advertising; business management; business administration; office functions.
US Class Codes100, 101, 102
Class Status Code6 - Active
Class Status DateFriday, May 2, 2025
Primary Code035
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class036 - Insurance; financial affairs; monetary affairs; real estate affairs.
US Class Codes100, 101, 102
Class Status Code6 - Active
Class Status DateFriday, May 2, 2025
Primary Code036
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, May 2, 2025
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameDebiopharm International SA
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressLausanne CH-1002
CH

Trademark Events

Event DateEvent Description
Friday, May 2, 2025NEW APPLICATION ENTERED
Friday, May 2, 2025APPLICATION FILING RECEIPT MAILED

Related Keywords

care triptodur disorders services support patient including affordability programs administration access drug